Methods for diagnosing Huntington's disease
View Patent ↗The disclosure provides methods for the diagnosis of Huntington's disease. In some embodiments, the method comprises detecting one or more repeat associated non-ATG (RAN) proteins in a biological sample.
1. A method for monitoring a Huntington's disease therapeutic regimen, the method comprising:
a. detecting in a second biological sample obtained from a subject that has been administered a therapeutic regimen for Huntington's disease a level of a repeat-associated non-ATG (RAN) protein, wherein the RAN protein is a poly-Alanine, poly-Leucine, poly-Serine, or poly-Cysteine RAN protein that is expressed from a human huntingtin (HTT) sense or antisense transcript of the subject;
b. comparing the level of the RAN protein to a level of the same RAN protein in a first sample obtained from the subject prior to being administered the therapeutic regimen; and
c. continuing to administer the therapeutic regimen for Huntington's disease when the level of the RAN protein in the second biological sample is reduced compared to the level of the first biological sample,
wherein the first biological sample and/or the second biological sample is blood, serum or cerebrospinal fluid (CSF).
2. The method of claim 1 , wherein the number of poly-amino acid repeats in the RAN protein is greater than or equal to 35.
3. The method of claim 1 , wherein the detecting is performed by immunoblot analysis, Western blot analysis, immunohistochemistry, or ELISA.
4. The method of claim 3 , wherein the Western blot analysis comprises contacting the sample with an anti-RAN antibody, wherein the anti-RAN antibody targets poly-Alanine, poly-Leucine, poly-Serine, or poly-Cysteine.
5. The method of claim 1 , wherein the RAN protein is expressed from an antisense transcript of human huntingtin (HTT).
6. The method of claim 4 , wherein the anti-RAN antibody targets the C-terminus of a RAN protein.